ISSN:
1776-260X
Content:
Gemcitabine, Objective Response Rate, KRAS Mutation, Disease Control Rate, Advanced Pancreatic Cancer
In:
Targeted oncology, Paris : Springer Verlag France S.A.R.L., 2006, 12(2017), 1, Seite 97-109, 1776-260X
In:
volume:12
In:
year:2017
In:
number:1
In:
pages:97-109
Language:
English
DOI:
10.1007/s11523-016-0469-y
Author information:
Michl, Patrick 1971-
Bookmarklink